Brainstorm Cell Therapeutics, Inc. (BCLI)
1.065
-0.06
(-5.19%)
USD |
OTCM |
Aug 31, 16:00
Brainstorm Cell Therapeutics Total Long Term Debt (Quarterly) : 0.00 for June 30, 2026
Total Long Term Debt (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Long Term Debt (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 0.00 |
| March 31, 2026 | 0.00 |
| December 31, 2025 | 0.00 |
| September 30, 2025 | 0.05M |
| June 30, 2025 | 0.095M |
| March 31, 2025 | 0.127M |
| December 31, 2024 | 0.171M |
| September 30, 2024 | 0.271M |
| June 30, 2024 | 0.396M |
| March 31, 2024 | 0.533M |
| December 31, 2023 | 0.672M |
| September 30, 2023 | 1.585M |
| June 30, 2023 | 1.938M |
| March 31, 2023 | 2.29M |
| December 31, 2022 | 2.666M |
| September 30, 2022 | 2.918M |
| June 30, 2022 | 3.264M |
| March 31, 2022 | 3.932M |
| December 31, 2021 | 3.618M |
| September 30, 2021 | 3.766M |
| June 30, 2021 | 4.004M |
| March 31, 2021 | 4.179M |
| December 31, 2020 | 4.562M |
| September 30, 2020 | 0.284M |
| June 30, 2020 | 0.559M |
| Date | Value |
|---|---|
| March 31, 2020 | 0.808M |
| December 31, 2019 | 1.103M |
| September 30, 2019 | 2.63M |
| June 30, 2019 | 2.837M |
| March 31, 2019 | 3.045M |
| December 31, 2018 | 0.00 |
| September 30, 2018 | 0.00 |
| June 30, 2018 | 0.00 |
| March 31, 2018 | 0.00 |
| December 31, 2017 | 0.00 |
| September 30, 2017 | 0.00 |
| June 30, 2017 | 0.00 |
| March 31, 2017 | 0.00 |
| December 31, 2016 | 0.00 |
| September 30, 2016 | 0.00 |
| June 30, 2016 | 0.00 |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 0.00 |
| June 30, 2015 | 0.00 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | 0.00 |
| September 30, 2014 | 0.00 |
| June 30, 2014 | 0.00 |
| March 31, 2014 | 0.00 |
Total Long Term Debt Definition
Represents a company's total debt maturing for more than 12 months of the reporting period.
Total Long Term Debt (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Long Term Debt (Quarterly) Benchmarks
| NovelStem International Corp. | 1.620M |
| Summit Therapeutics, Inc. | 16.83M |
| Kezar Life Sciences, Inc. | 0.00 |
| Protara Therapeutics, Inc. | 1.463M |
| Clene, Inc. | 21.53M |